, and ACH-1625, a protease inhibitor also for the treating chronic hepatitis C. Related StoriesWhy perform we sleep?6 million or $0.16 per share, weighed against a net loss of $6.7 million or $0.25 per share for the first quarter of 2009.0 million, up $15.3 million compared with December 31, 2009. SOURCE MicroStockProfit.com.. ACHN reports net lack of $5.6M for first-quarter 2010: MicroStockProfit.com MicroStockProfit.com announces an investment survey featuring Achillion Pharmaceuticals Inc.The largest gains were noticed with the 210-mg monthly dose of romosozumab, with mean boosts from baseline to 12 months of 11.3 percent at the lumbar spine, 4.1 percent at the total hip, and 3.7 percent at the femoral neck. These increases were significantly greater than those observed in the alendronate and teriparatide groups . No noteworthy differences in bone mineral density at the distal third of the radius were observed at 12 weeks between the romosozumab groupings and the pooled placebo group, the alendronate group, or the teriparatide group .006) . The raises in bone mineral density at the femoral neck were significantly higher at month 6 in the groupings that received romosozumab in doses of 140 mg monthly, 210 mg regular monthly, and 210 mg every 3 months than in the pooled placebo group .01).